Pulmonx Corporation

LUNG Healthcare Medical Devices

Pulmonx Corporation’s revenue for fiscal 2025 (year ended December 2025) was $90.5 million, up 8.01% from fiscal 2024. In the quarter to June 2026, revenue fell 4.62%, EPS grew 36.8%, free cash flow fell 31.8% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years.

1.78 0.07 −3.78%
Market cap
$79.5M
P/E
0.0×
Fwd P/E
−1.3×
Dividend yield
—
F-score
3/9
Altman Z
−4.84
Beneish M
−3.38
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Older periods Sep '25 Dec '25 Mar '26 Jun '26
Total current assets
111.24 101.68 92.75 88.13
Total non-current assets
27.05 27.61 27.22 26.60
Total Assets
138.28 129.29 119.97 114.73
Total current liabilities
22.88 20.06 18.91 20.41
Total non-current liabilities
55.37 55.12 55.30 55.13
Total liabilities
78.25 75.18 74.21 75.54
Common Equity (Total)
60.03 54.12 45.76 39.20
Shareholders Equity (Total)
60.03 54.12 45.76 39.20
Total Debt
37.13 36.99 37.21 37.43

Show all line items

In millions of $ except per-share values · columns are period end dates